Indian Journal of Ophthalmology

: 2007  |  Volume : 55  |  Issue : 6  |  Page : 417--420

Bevacizumab: Off-label use in ophthalmology

Salvatore Grisanti, Focke Ziemssen 
 University Eye Hospital at the Centre of Ophthalmology, Eberhard-Karls University of Tuebingen, Germany

Correspondence Address:
Salvatore Grisanti
University Eye Hospital, Centre of Ophthalmology, Eberhard-Karls University of Tuebingen Schleichstrasse 12-15 72076 Tuebingen

Bevacizumab is a full-length, humanized monoclonal antibody directed against all the biologically active isoforms of vascular endothelial growth factor (VEGF-A). The antibody was initially designed and studied as an anti-angiogenic strategy to treat a variety of solid tumors. After approval by the US Food and Drug Administration, bevacizumab gained access into ophthalmology to treat various types of neovascular diseases. Since the first report in 2005 more than 100 publications share the experience with bevacizumab in ophthalmology. Two authors independently assessed the research results from Pubmed to April 2007. The reference list is a selection of key publications related to the issue. Currently, there is no well-designed randomized controlled trial yet to establish the efficacy and safety of intraocular bevacizumab for any ocular disease in spite of its assumed characteristics representing the most cost-effective VEGF inhibitor.

How to cite this article:
Grisanti S, Ziemssen F. Bevacizumab: Off-label use in ophthalmology.Indian J Ophthalmol 2007;55:417-420

How to cite this URL:
Grisanti S, Ziemssen F. Bevacizumab: Off-label use in ophthalmology. Indian J Ophthalmol [serial online] 2007 [cited 2020 Sep 27 ];55:417-420
Available from:;year=2007;volume=55;issue=6;spage=417;epage=420;aulast=Grisanti;type=0